in vivo– tag –
-
Frontiers Review Highlights RNA-Based Drugs’ Transformative Role in Modern Medicine, Emphasizing siRNA, mRNA, and ASO Delivery Strategies
Frontiers Switzerland Overview A Frontiers review comprehensively outlines the evolution of RNA therapeutics into innovative medical approaches by directly targeting disease-related RNA molecules. The review highlights the mechanisms of ... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and... -
Oregon State University Develops Novel Sugar-Coated Nanoparticle Therapy for Glioblastoma: Boosting Mouse Survival by 50%
Oregon State University via Medical Xpress USA Overview Researchers at Oregon State University have developed a new experimental glioblastoma treatment using sugar-coated nanoparticles to deliver genetic instructions that restore a tumor... -
Modular In Vivo Antibody-ADC Click Strategy Reverses Drug Resistance in Tumors
PubMed (Nature Chemical Biology) USA Overview Researchers have introduced an in vivo bioorthogonal ligation strategy to generate functional antibody-drug conjugate (ADC) click constructs following systemic administration. This modular pl... -
Alloy Therapeutics Unveils AntiClastic™ Cyclic RNA Platform for Enhanced Potency and Reduced Off-Target Effects in Next-Gen RNA Medicines
Alloy Therapeutics USA Overview Alloy Therapeutics introduced its AntiClastic™ Cyclic Oligonucleotide platform, which reconfigures ASOs, siRNAs, and sgRNAs into proprietary cyclic architectures. This technology aims to enhance potency an... -
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
REPROCELL Enhances 3D Cell Culture Product Portfolio with Alvetex® & EZSPHERE™ to Advance Drug Discovery Translational Research
REPROCELL Japan Overview REPROCELL is fortifying its diverse 3D cell culture product lines, including Alvetex® 3D Cell Culture Systems and the Alvetex® Advanced Tissue Bioengineering System, to provide biologically relevant, reproducible... -
MaxCyte & VectorBuilder Partner on Virus-Free Gene Delivery Platform for Ex Vivo Cell Therapies, Boosting CAR T-Cell Manufacturability
BioProcess International USA Overview CDMO VectorBuilder and MaxCyte have partnered to develop a virus-free gene delivery platform for ex vivo cell therapies, including CAR T cells. This collaboration integrates VectorBuilder's 'MiniVec'... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ...
